Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Pelthos Therapeutics Inc.AMEX: PTHS
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 15854.9% from a year ago
Total assets stood at $145.38M at the end of Q1 FY2026, up 15854.9% from a year earlier and up 11.5% from the prior quarter. Over 3 fiscal years it compounded at +1232.8% a year.
Context
- Total assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +15854.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 130.4M USD
- Year-over-year change
- +9424.0%
- 3-year CAGR
- +1232.8%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 130.4M | +9424.0% |
| FY2024 | 2024-12-31 | 1.37M | +1320.4% |
| FY2023 | 2023-12-31 | 96.39K | +75.0% |
| FY2022 | 2022-12-31 | 55.07K | — |
Total Assets vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 total assets of $145.38M is the 2nd highest of the 4 companies compared; the peer median is $30.86M.
- Its year-over-year change of +15854.9% is the highest of 4, against a peer median of +617.5%.
- Over three fiscal years its annual growth of +1232.8% compares with a peer median of +31.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Dec 2025 | $2.33B | +8304.7% | +225.2% | |
| Mar 2026 | $145.38M | +15854.9% | +1232.8% | |
| Mar 2026 | $30.86M | +147.5% | +9.7% | |
| Mar 2026 | $10.87M | +617.5% | +31.8% | |
| Peer median (excluding PTHS) | $30.86M | +617.5% | +31.8% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.